Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1947 3
1948 2
1949 4
1950 6
1951 9
1952 6
1953 2
1954 1
1955 5
1956 6
1957 2
1958 6
1959 5
1960 4
1961 4
1962 5
1963 14
1964 22
1965 21
1966 20
1967 33
1968 45
1969 39
1970 41
1971 56
1972 83
1973 79
1974 73
1975 90
1976 71
1977 64
1978 56
1979 66
1980 46
1981 50
1982 51
1983 59
1984 72
1985 71
1986 83
1987 65
1988 72
1989 78
1990 95
1991 106
1992 89
1993 96
1994 100
1995 84
1996 83
1997 79
1998 75
1999 86
2000 90
2001 126
2002 137
2003 164
2004 216
2005 296
2006 284
2007 326
2008 399
2009 421
2010 570
2011 611
2012 664
2013 708
2014 583
2015 525
2016 487
2017 483
2018 465
2019 256
2020 17
Text availability
Article attribute
Article type
Publication date

Search Results

9,418 results
Results by year
Filters applied: . Clear all
Page 1
Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy.
Friedlander M, et al. Br J Cancer 2018 - Clinical Trial. PMID 30353045 Free PMC article.
BACKGROUND: In Study 19, maintenance monotherapy with olaparib significantly prolonged progression-free survival vs placebo in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer. METHODS: Study 19 was a randomised, placebo-controlled, Phase II trial enrolling 265 patients who had received at least two platinum-based chemotherapy regimens and were in complete or partial response to their most recent regimen. ...
BACKGROUND: In Study 19, maintenance monotherapy with olaparib significantly prolonged progression-free survival vs placebo in patients with …
Mechanisms of Chemotherapy-Induced Peripheral Neuropathy
Zajączkowska R, et al. Int J Mol Sci 2019 - Review. PMID 30909387 Free PMC article.
There are six main substance groups that cause damage to peripheral sensory, motor and autonomic neurons, which result in the development of CIPN: platinum-based antineoplastic agents, vinca alkaloids, epothilones (ixabepilone), taxanes, proteasome inhibitors (bortezomib) and immunomodulatory drugs (thalidomide). Among them, the most neurotoxic are platinum-based agents, taxanes, ixabepilone and thalidomide; other less neurotoxic but also commonlyused drugs are bortezomib and vinca alkaloids. ...
There are six main substance groups that cause damage to peripheral sensory, motor and autonomic neurons, which result in the development of …
IL-6 mediates platinum-induced enrichment of ovarian cancer stem cells.
Wang Y, et al. JCI Insight 2018. PMID 30518684 Free PMC article.
Inflammatory cytokine IL-6 is elevated in residual tumors after platinum treatment, and we hypothesized that IL-6 plays a critical role in platinum-induced OCSC enrichment. ...We show that platinum induces IL-6 secretion by cancer-associated fibroblasts in the tumor microenvironment, promoting OCSC enrichment in residual tumors after chemotherapy. ...
Inflammatory cytokine IL-6 is elevated in residual tumors after platinum treatment, and we hypothesized that IL-6 plays a critical ro …
Immunotherapy: last bullet in platinum refractory germ cell testicular cancer.
Semaan A, et al. Future Oncol 2019 - Review. PMID 30624089
However, patients with platinum-refractory and relapsing tumors after autologous stem cell transplant have very poor outcomes despite salvage treatments, and with no effective alternative therapies. ...
However, patients with platinum-refractory and relapsing tumors after autologous stem cell transplant have very poor outcomes despite …
Autocrine activation of JAK2 by IL-11 promotes platinum drug resistance.
Zhou W, et al. Oncogene 2018. PMID 29662190 Free PMC article.
Antineoplastic platinum agents are used in first-line treatment of ovarian cancer, but treatment failure frequently results from platinum drug resistance. ...These findings not only identify a novel ROS-IL-11-JAK2-mediated platinum resistance mechanism but also provide a new strategy for using LY2784544- or IL-11-mediated immunotherapy to treat platinum-resistant ovarian cancer....
Antineoplastic platinum agents are used in first-line treatment of ovarian cancer, but treatment failure frequently results from p
Platinum-induced muscle wasting in cancer chemotherapy: Mechanisms and potential targets for therapeutic intervention.
Moreira-Pais A, et al. Life Sci 2018 - Review. PMID 30146014
Platinum-based drugs are among the most effective anticancer therapies, integrating the standard of care for numerous human malignancies. ...Herein, we review the molecular mechanisms proposed to be involved in chemotherapy-related muscle wasting with a focus on the typical platinum-based drug cisplatin. ...
Platinum-based drugs are among the most effective anticancer therapies, integrating the standard of care for numerous human malignanc
Irinotecan-platinum combination therapy for previously untreated extensive-stage small cell lung cancer patients: a meta-analysis.
Xu F, et al. BMC Cancer 2018. PMID 30097029 Free PMC article.
Regimens combining irinotecan and platinum improved overall survival, progression-free survival and overall response rate compared to combination etoposide and platinum regimens. ...And the Asian patients could benefit from irinotecan combined with platinum easier....
Regimens combining irinotecan and platinum improved overall survival, progression-free survival and overall response rate compared to …
Impact of aging on the risk of platinum-related renal toxicity: A systematic review and meta-analysis.
Duan ZY, et al. Cancer Treat Rev 2018 - Review. PMID 30121504
BACKGROUND: Renal toxicity limits the clinical use of platinum-based therapy in the elderly. In order to clarify the impact of aging on the risk of platinum-related nephrotoxicity, the following meta-analysis was performed. ...The risk of platinum-related nephrotoxicity in elderly patients was significantly increased in the high comorbidity rate group. ...
BACKGROUND: Renal toxicity limits the clinical use of platinum-based therapy in the elderly. In order to clarify the impact of aging …
An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023.
Shoji T, et al. BMC Cancer 2018 - Clinical Trial. PMID 30064406 Free PMC article.
BACKGROUND: We present the study rationale and design of the JGOG3023 study, an open-label, parallel-arm, randomized, phase II trial that aimed to assess the efficacy and safety of chemotherapy with or without bevacizumab in patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who were previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer. ...METHODS/DESIGN: A total of 106 patients who have recurrence or progression of ovarian cancer, while receiving chemotherapy or within 6 months after the final dose of platinum, after completing at least three cycles of bevacizumab plus platinum chemotherapy will be randomized in a 1:1 ratio to treatment with single-agent chemotherapy or single-agent chemotherapy combined with bevacizumab. ...
BACKGROUND: We present the study rationale and design of the JGOG3023 study, an open-label, parallel-arm, randomized, phase II trial that ai …
[Research progress of copper transporter 1 in platinum-based chemotherapy].
Ouyang Q, et al. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2018 - Review. PMID 30643056 Chinese. Free article.
CTR1 is also the major platinum influx transporter and plays a key role in platinum resistance. The expression, polymorphism, and degradation of CTR1 affect platinum resistance in tumors. Therefore, CTR1 may be a potential predictive biomarker of platinum resistance and a therapeutic target for overcoming platinum resistance....
CTR1 is also the major platinum influx transporter and plays a key role in platinum resistance. The expression, polymorphism, …
9,418 results
Jump to page
Feedback